Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)
01:19am, Tuesday, 30'th May 2023
Madrigal Pharmaceuticals' drug, resmetirom, for non-alcoholic fatty liver diseases, received FDA's Breakthrough Therapy designation. The company is now focused on the MAESTRO-NASH-OUTCOMES trial. Madr
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
01:17pm, Wednesday, 24'th May 2023
The shares are continuing a yearlong winning streak today. This latest uptick appears to be the result of two tailwinds.
Why These 3 Nasdaq Stocks Buckled Today
03:42pm, Tuesday, 16'th May 2023
The Federal Trade Commission is suing to block the proposed merger between Amgen and Horizon Therapeutics. This adverse regulatory action rippled out across the small- and mid-cap biotech landscape to
Why Madrigal Pharmaceuticals Stock Is Slumping Today
01:54pm, Tuesday, 09'th May 2023
Madrigal Pharmaceuticals stock plummeted in early-morning trading following its 2023 Q1 earnings report. Bargain hunters were quick to buy the dip, however.
3 Biotechs That Might Get Bought Out in 2023
11:30am, Wednesday, 26'th Apr 2023
With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
02:06pm, Thursday, 20'th Apr 2023
On Tuesday, Madrigal won an important regulatory designation from the FDA for its NASH candidate. The biotech got another boost from the ongoing buyout bonanza in biotech.
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
08:07am, Thursday, 20'th Apr 2023
Where is the current bull market? All indications would be that it's in biotech!
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
03:12pm, Wednesday, 19'th Apr 2023
Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.
Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout
12:00pm, Tuesday, 18'th Apr 2023
Madrigal snagged a breakthrough therapy designation for its liver disease treatment on Tuesday and MDGL stock surged closer to a buy point. The post Why Top 1% Biotech Madrigal Pharmaceuticals Just Su
These Are the Top 10 Holdings of Avoro Capital Advisors
10:54pm, Monday, 17'th Apr 2023
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
5 Best Stocks to Buy in April
01:43pm, Saturday, 01'st Apr 2023
Several key themes are emerging in the stock investing landscape. These five stocks are poised to benefit from these powerful trends.
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
11:40pm, Wednesday, 29'th Mar 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
12:29pm, Friday, 10'th Mar 2023
Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Fac
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
11:49am, Friday, 10'th Mar 2023
Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble. The post Intercept Tumbles As Its Experimental NASH Drug Fac
1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030
01:56pm, Thursday, 09'th Mar 2023
The stock market tends to be efficient at pricing equities, but not always. Experimental drug developers in particular have often turned out to be wildly mispriced by skeptical investors.
